These results support the analysis of multiple mutations in ctDNA to improve prognosis prediction, as well as combination therapy with the PIK3CA inhibitor drug alpelisib, which is currently only available for the treatment of advanced breast cancer. Here, PIK3CA is linked to breast cancer.